CVBT Founder Thomas J. Stegmann, M.D., Elected to Ukranian Academy of Medical Sciences.

LAS VEGAS -- CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) today announced that co-founder and Co-President, Prof. Dr. Thomas J. Stegmann, M.D., has received the prestigious international honor of being elected as full member of the Ukrainian Academy of Medical Sciences.

In the presence of Vice Prime Minister of Ukraine Dmytro Tabachnyk, Dr. Stegmann unanimously was elected by all 98 distinguished members of the Academy during an event hosted by Prof Dr. Aleksandr Vozianov, President of the Ukrainian Academy of Medical Sciences. Membership into the Academy is a lifetime appointment, and only a few foreign scientists have received the honor of being elected as full member. The Ukrainian Academy of Medical Sciences was founded in 1918, and today represents all major medical and scientific institutions in Ukraine. It is the most elite health care council in Ukraine and the Academy's budget is financed by the federal government.

At the July 4th event in Kiev, Dr. Stegmann presented his recent scientific contributions in a talk entitled "Angiogenesis - A New Principle of Treatment for Cardiovascular Diseases."

"I am greatly honored, and deeply touched by this extraordinary recognition presented to me by my Ukrainian friends," Dr. Stegmann stated. "This honor and appointment is also the result of many other individuals who have worked with me and served as my colleagues through the years, including German heart surgeons, American scientists from Nevada and California, and visionary business leaders who are now working with me to make angiogenesis therapy a medical reality."

Dr. Stegmann was the first surgeon to successfully accomplish angiogenesis therapy in the human heart. In a series of ground-breaking European clinical trials in the 1990s, Dr. Stegmann showed the potential of protein-based growth factor therapy to grow new blood vessels in the heart, and to give patients with advanced coronary artery disease a lasting clinical benefit. This work led to the establishment of CardioVascular BioTherapeutics, Inc. to commercialize this discovery.

"I take this honor as a representative for CardioVascular BioTherapeutics, Inc and know this recognition is an incentive for further research and clinical development of protein-based angiogenic therapy for patients suffering from all forms of atherosclerotic diseases," he added.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with human fibroblast growth factor-1 (FGF-1) as their active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to a tissue or organ. The company has three clinical trials underway with drug candidates to treat the following medical indications: severe Coronary Heart Disease (CVBT-141A), dermal wound healing in diabetics (CVBT-141B), and Peripheral Arterial Disease (CVBT-141C).

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.